Journal profile · Multiple
JACC: CardioOncology
ISSN 2666-0873 · ELSEVIER · UNITED STATES
JACC: CardioOncology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 14.92; fully open access; APC about USD 4,410; review about 16 weeks (community reports); 133 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
JACC: CardioOncology is published by ELSEVIER and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Chemotherapy-induced cardiotoxicity and mitigation, Cardiac Imaging and Diagnostics and Amyloidosis: Diagnosis, Treatment, Outcomes, together about 42% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
JACC: CardioOncology is one of a family of specialist journals launched by the renowned Journal of the American College of Cardiology (JACC) . It serves to advance the cardiovascular care of cancer patients through the publication of rigorously executed, innovative science and dissemination of evidence-based knowledge. The journal seeks to transform the field of cardio-oncology and actively engage and educate the cardiovascular and oncology communities in pre-clinical, translational, and clinical research, as well as in best practices in cardio-oncology. Broad areas of interest include original research studies in disease mechanisms, in vitro and in vivo model systems, novel and conventional therapeutics (Phase I-IV), epidemiology, precision medicine, and primary and secondary prevention. Disease states of interest include, but are not limited to amyloidosis, cardiovascular risk factors, heart failure, and vascular disease.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Bonnie KyPublisher website
Editorial board by country: 7 in mainland China (about 4%); most named United States 118, United Kingdom 10, Mainland China 7, Italy 7, Spain 5 (167 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Chemotherapy-induced cardiotoxicity and mitigationMedicine28.6%
- Cardiac Imaging and DiagnosticsMedicine7.8%
- Amyloidosis: Diagnosis, Treatment, OutcomesBiochemistry, Genetics and Molecular Biology5.6%
- Cancer Treatment and PharmacologyMedicine4.5%
- Cardiovascular Function and Risk FactorsMedicine4.1%
- Cancer Immunotherapy and BiomarkersMedicine3.6%
- Venous Thromboembolism Diagnosis and ManagementMedicine3.5%
- Cardiac tumors and thrombiMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cardiac & Cardiovascular Systems | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Cardiac & Cardiovascular Systems | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cardiac & Cardiovascular Systems | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.92LetPub ·
- Impact factor (publisher)
- 15.5Publisher website ·
- CiteScore 2026-06
- 16.3LetPub ·
- CiteScore (publisher)
- 16.3Publisher website ·
- SJR 2026-06
- 3.84LetPub ·
- SNIP 2026-06
- 2.68LetPub ·
- h-index
- 64OpenAlex ·
- i10-index
- 350OpenAlex ·
- 2-year mean citedness
- 7.05OpenAlex ·
- Self-citation rate
- 8.4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 52LetPub ·
Articles by year OpenAlex count · 984 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 97 | 97 | 50 |
| 2025 | 133 | 133 | 687 |
| 2024 | 149 | 149 | 1,936 |
| 2023 | 136 | 136 | 2,077 |
| 2022 | 154 | 154 | 2,971 |
| 2021 | 122 | 122 | 3,649 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed
Not usableThis publisher's "received" date is mostly when the revised manuscript arrived (37% of articles were "accepted" within 3 days), so it cannot measure review time
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,410 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,200 / EUR 3,930 / GBP 3,360 / JPY 520,930 | — | — | |
| LetPub | USD 2,500 | Yes | — | |
| Publisher website | USD 4,410 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- Numbered, in order of citation
- Highlights
- Required
Article types accepted11, with length limits
- clinical case challengeArticle Types Original Investigations State-Of-The-Art Reviews Primers In Cardio-Oncology Research Letters Viewpoints Clinical Case Challenge Letters To The Edi…Length not stated
- letters to the editorJACC: CardioOncology will publish a limited number of letters that focus on a specific manuscript that has appeared in the journal. Letters must be submitted wi…main text ≤ 500 words
- letters to the editor and repliesLetters To The Editor And Replies JACC: CardioOncology will publish a limited number of letters that focus on a specific manuscript that has appeared in the jou…Length not stated
- original investigationsArticle Types Original Investigations State-Of-The-Art Reviews Primers In Cardio-Oncology Research Letters Viewpoints Clinical Case Challenge Letters To The Edi…Length not stated
- original researchnal Investigations JACC: CardioOncology original research manuscripts should not exceed 5,000 words (including text from the introduction to conclusion, referemain text ≤ 5,000 words
- primers in cardio-oncologyArticle Types Original Investigations State-Of-The-Art Reviews Primers In Cardio-Oncology Research Letters Viewpoints Clinical Case Challenge Letters To The Edi…Length not stated
- research lettersArticle Types Original Investigations State-Of-The-Art Reviews Primers In Cardio-Oncology Research Letters Viewpoints Clinical Case Challenge Letters To The Edi…Length not stated
- reviewJACC: CardioOncology uses a single-blind peer-review system, meaning that the authors are blinded to the identity of the reviewers and as a general rule, althou…Length not stated
- state-of-the-art reviewsState-Of-The-Art Reviews The Editors will consider both invited and volunteered review articles on a highly relevant topic in cardio-oncology.Length not stated
- viewpointAlthough usually invited, succinct opinion pieces relevant to a specific aspect of cardio-oncology will also be considered for JACC: CardioOncology. They should…main text ≤ 2,000 words
- viewpointsArticle Types Original Investigations State-Of-The-Art Reviews Primers In Cardio-Oncology Research Letters Viewpoints Clinical Case Challenge Letters To The Edi…Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism
- Authorship Authorship/Cover Letter
Manuscript submissions should conform to the guidelines set forth in the “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations),” available online at https://www.icmje.org/recommendations and most recently updated in December 2019.Each author must have contributed significantly to the submitted work. The contribution of ea…
Source ↗Publisher website ·- Conflicts of interest
Relationship with industry disclosure policy Model summary
All authors are required to disclose any relationship with industry and other relevant entities-financial or otherwise-within the past 2 years that might pose a conflict of interest in connection with the submitted article.
Source ↗Publisher website ·- Publication ethics
Ethics policy conforming to ICMJE Recommendations Model summary
Manuscript submissions should conform to the guidelines set forth in the “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations),” available online at https://www.icmje.org/recommendations and most recently updated in December 2019.
Source ↗Publisher website ·- License & copyright Copyright
Permissions policy for reprinted material Model summary
On acceptance, transfer of copyright to the author(s) will occur (for more information see https://www.elsevier.com/OAauthoragreement). Permitted third party reuse of open access articles is determined by the author's choice of user license (see https://www.elsevier.com/about/policies/open-access-licenses). As an author you (or your employer or institution) have certain rights to reuse your work. …
Source ↗Publisher website ·- Open access Open Access
Open access papers published under a noncommercial license; commercial CC BY license can be applied for after acceptance Model summary
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Review Process And Decisions
Exclusive submission/publication policy Model summary
JACC: CardioOncology uses a single-blind peer-review system, meaning that the authors are blinded to the identity of the reviewers and as a general rule, although there are exceptions, the reviewers are blinded to each other. While the JACC: CardioOncology Associate Editor may be identified at the end of the review process, all correspondence concerning a manuscript should be addressed to the JACC…
Source ↗Publisher website ·- Plagiarism
Originality verification via Crossref Similarity Check Model summary
To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- ELSEVIER
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2666-0873
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about JACC: CardioOncology
What CAS zone is JACC: CardioOncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, JACC: CardioOncology is in Zone 1 of Medicine, and in Zone 1 of the minor category Cardiac & Cardiovascular Systems / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of JACC: CardioOncology?
The latest impact factor listed by LetPub is 14.92; CiteScore 16.3, h-index 64.
How long does peer review take at JACC: CardioOncology?
Authors report an average review time of about 16 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of JACC: CardioOncology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: Numbered, in order of citation; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of JACC: CardioOncology based?
Of the 167 board members whose country the journal's board page names, 7 (about 4%) are in mainland China; the countries named most often are United States (118), United Kingdom (10) and Mainland China (7). Counted from the institutions listed on the board page; for reference only.
Which databases index JACC: CardioOncology?
According to LetPub and DOAJ records, JACC: CardioOncology is indexed in SCIE, Scopus and DOAJ.
Is JACC: CardioOncology open access, and what is the APC?
JACC: CardioOncology is a fully open-access journal. APC about USD 4,410.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .